Moderna, Inc. (FRA:0QF)

Germany flag Germany · Delayed Price · Currency is EUR
28.86
+2.50 (9.50%)
At close: Dec 19, 2025
-23.04%
Market Cap11.27B
Revenue (ttm)1.90B
Net Income (ttm)-2.66B
Shares Outn/a
EPS (ttm)-6.86
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume153
Average Volume1,498
Open26.10
Previous Close26.36
Day's Range26.10 - 28.86
52-Week Range19.26 - 49.20
Betan/a
RSI77.17
Earnings DateFeb 20, 2026

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5,800
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 0QF
Full Company Profile

Financial Performance

In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.

Financial numbers in USD Financial Statements

News

Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth

Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth

4 days ago - GuruFocus

Moderna, Inc.: Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:3...

4 days ago - Finanz Nachrichten

Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...

4 days ago - Wallstreet:Online

Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...

4 days ago - Accesswire

Pfizer leads COVID-19 vaccine peers lower after revamped guidance

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company issues a disappointing outlook. Read more here.

5 days ago - Seeking Alpha

XOMA Royalty Enters into Agreement to Acquire Generation Bio

- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) deliv...

6 days ago - Wallstreet:Online

Moderna Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ: MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled...

6 days ago - Benzinga

Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders

Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders

6 days ago - GuruFocus

Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine

Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine

6 days ago - GuruFocus

Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE

mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in t...

6 days ago - Finanz Nachrichten

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)

mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the ...

6 days ago - Wallstreet:Online

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)

mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the...

6 days ago - Accesswire

Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges

Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges

9 days ago - GuruFocus

Short bets on S&P 500 Healthcare sector rises to 2.12% in November; MRNA stays most shorted stock

The S&P 500 Healthcare sector (XLV) experienced a rise in average short interest during November, moving from 1.97% to 2.12%. Within this sector, Moderna (MRNA) remains the most heavily shorted stock....

9 days ago - Seeking Alpha

Moderna (MRNA) Q4 2024 Earnings Call Transcript

Moderna (MRNA) Q4 2024 Earnings Call Transcript

10 days ago - The Motley Fool

Is the Market Bullish or Bearish on Moderna Inc?

Moderna Inc's (NYSE: MRNA) short interest as a percent of float has risen 5.79% since its last report. According to exchange reported data, there are now 68.08 million shares sold short , which is 21...

10 days ago - Benzinga

MRNA January 2026 Options Begin Trading

Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA option...

10 days ago - Nasdaq

Moderna (MRNA) Q3 2024 Earnings Call Transcript

Moderna (MRNA) Q3 2024 Earnings Call Transcript

10 days ago - The Motley Fool

Moderna (MRNA) Q1 2025 Earnings Call Transcript

Moderna (MRNA) Q1 2025 Earnings Call Transcript

10 days ago - The Motley Fool

Moderna (MRNA) Q2 2025 Earnings Call Transcript

Moderna (MRNA) Q2 2025 Earnings Call Transcript

10 days ago - The Motley Fool

Moderna (MRNA) Q3 2025 Earnings Call Transcript

Moderna (MRNA) Q3 2025 Earnings Call Transcript

10 days ago - The Motley Fool

Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?

Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?

10 days ago - GuruFocus

Moderna (MRNA) Faces Challenges Amid Declining Vaccine Research Funding

Moderna (MRNA) Faces Challenges Amid Declining Vaccine Research Funding

10 days ago - GuruFocus